C5 and COVID-19: These findings suggest that targeting the C5a–C5aR1 axis could control the SARS-CoV-2/GC-induced excess production of chemokines, tissue recruitment of immune cells, pro-inflammatory cytokines production and lessen the resultant tissue damage in COVID-19 and GD patients.